Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDRO-PROTECT
2022-500210-26-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Tolvaptan + hydrochlorothiazide with Tolvaptan + placebo (2 arms). Planned start Jun 2023; status: authorised.
02
Drugs
hydrochlorothiazide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2022-500210-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500210-26-00.